Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Relacorilant in combinatie met NAB-Paclitaxel en bevacizumab in gevorderde, epitheliale eierstok, primaire peritoneale of eileider-buiskanker

10 november 2026 bijgewerkt door: Corcept Therapeutics

Een fase 2-studie van relacorilant in combinatie met NAB-paclitaxel en bevacizumab in geavanceerde, epitheliale eierstok, primaire peritoneale of eileider-buiskanker (Bella)

This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.

Studie Overzicht

Gedetailleerde beschrijving

This study is designed with the goal to add additional arms as new treatments become available. All arms will follow an independent and parallel design.

For Arms A and B, study treatment will comprise relacorilant combined with nab-paclitaxel, and bevacizumab and will begin on Cycle 1 Day 1 (C1D1). Each patient will receive relacorilant 150 mg administered orally under fed conditions, once daily for 3 consecutive days on the day before, the day of, and the day after nab-paclitaxel infusion (in Cycle 1 relacorilant is only given on 2 consecutive days, starting on C1D1), in combination with nab-paclitaxel (80 mg/m^2 intravenously [IV]) administered on Days 1, 8, and 15 of each 28-day cycle. Bevacizumab (10 mg/kg IV once every 2 weeks [Q2W]) will be administered on Days 1 and 15 of each 28-day cycle. Study treatment for Arm C will be similar to Arm A but does not include bevacizumab. Patients will receive treatment until they reach a protocol-defined event of progressive disease (PD), experience an unmanageable toxicity, or until other treatment discontinuation criteria are met.

Studietype

Ingrijpend

Inschrijving (Geschat)

270

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

      • Brussels, België, 1200
        • Werving
        • 109
      • Charleroi, België, 6000
        • Werving
        • 326
      • Hasselt, België, 3500
        • Werving
        • 325
      • Leuven, België, 3000
        • Werving
        • 108
    • Belgium
      • Aalst, Belgium, België, 9300
        • Werving
        • 328
      • Aachen, Duitsland, 52074
        • Werving
        • 519
      • Berlin, Duitsland, 10117
        • Werving
        • 255
      • Kempten, Duitsland, 87439
        • Werving
        • 520
      • Lille, Frankrijk, 59000
        • Werving
        • 306
      • Nancy, Frankrijk, 54100
        • Werving
        • 307
      • Nice, Frankrijk, 06100
        • Werving
        • 310
      • Pierre-Bénite, Frankrijk, 69495
        • Werving
        • 324
      • Plérin, Frankrijk, 22190
        • Werving
        • 323
      • Toulouse, Frankrijk, 31059
        • Werving
        • 308
      • Catania, Italië, 95126
        • Werving
        • 321
      • Milan, Italië, 20141
        • Werving
        • 122
      • Milan, Italië, 20159
        • Werving
        • 516
      • Pavia, Italië, 27100
        • Werving
        • 295
      • Rome, Italië, 00168
        • Werving
        • 124
      • Torino, Italië, 10128
        • Werving
        • 293
      • Treviso, Italië, 31100
        • Werving
        • 319
      • Gdynia, Polen, 81-519
        • Werving
        • 341
      • Siedlce, Polen, 08-MO
        • Werving
        • 329
      • Badalona, Spanje, 08916
        • Werving
        • 349
      • Barcelona, Spanje, 08035
        • Werving
        • 115
      • Madrid, Spanje, 28034
        • Werving
        • 114
      • Valencia, Spanje, 46026
        • Werving
        • 330
      • Valencia, Spanje, 46010
        • Werving
        • 558
    • Alabama
      • Birmingham, Alabama, Verenigde Staten, 35233
        • Werving
        • 004
    • California
      • Palo Alto, California, Verenigde Staten, 94304
        • Werving
        • 150
      • San Francisco, California, Verenigde Staten, 94109
        • Werving
        • 278
      • San Francisco, California, Verenigde Staten, 94143
        • Werving
        • 014
    • Colorado
      • Aurora, Colorado, Verenigde Staten, 80045
        • Werving
        • 032
    • Florida
      • Fort Myers, Florida, Verenigde Staten, 33901
        • Werving
        • 544
      • Miami Beach, Florida, Verenigde Staten, 33140
        • Werving
        • 335
      • West Palm Beach, Florida, Verenigde Staten, 33041
        • Werving
        • 543
    • Illinois
      • Chicago, Illinois, Verenigde Staten, 60637
        • Werving
        • 001
    • Minnesota
      • Minneapolis, Minnesota, Verenigde Staten, 55404
        • Werving
        • 518
    • Missouri
      • Kansas City, Missouri, Verenigde Staten, 64132
        • Werving
        • 334
      • St Louis, Missouri, Verenigde Staten, 63110
        • Werving
        • 521
    • New Mexico
      • Albuquerque, New Mexico, Verenigde Staten, 97102
        • Werving
        • 292
    • Ohio
      • Centerville, Ohio, Verenigde Staten, 45459
        • Werving
        • 304
    • Oregon
      • Eugene, Oregon, Verenigde Staten, 97401
        • Werving
        • 517
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Verenigde Staten, 15213
        • Werving
        • 127
    • Virginia
      • Fairfax, Virginia, Verenigde Staten, 22031
        • Werving
        • 522
      • Norfolk, Virginia, Verenigde Staten, 23502
        • Werving
        • 300
    • Wisconsin
      • Milwaukee, Wisconsin, Verenigde Staten, 53226
        • Werving
        • 121
    • Gangnam-gu
      • Seoul, Gangnam-gu, Zuid -Korea, 06351
        • Werving
        • 396
    • Goyang-si
      • Gyeonggi-do, Goyang-si, Zuid -Korea, 10408
        • Werving
        • 397
    • Jongno-gu
      • Seoul, Jongno-gu, Zuid -Korea, 03080
        • Werving
        • 399
    • Seocho-gu
      • Seoul, Seocho-gu, Zuid -Korea, 06591
        • Werving
        • 523
    • Seodaemun-gu
      • Seoul, Seodaemun-gu, Zuid -Korea, 03722
        • Werving
        • 398
    • Songpa-gu
      • Seoul, Songpa-gu, Zuid -Korea, 05505
        • Werving
        • 403

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Vrouw

Beschrijving

Inclusion Criteria:

Arms A and B

  • Histologic diagnosis of epithelial ovarian, primary peritoneal, or fallopian-tube carcinoma
  • Arm A Only: Platinum-resistant disease
  • Arm B Only: Platinum-sensitive disease who had progression while receiving treatment with a poly(ADP-ribose) polymerase (PARP) inhibitor
  • Life expectancy of ≥3 months
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Able to swallow and retain oral medication
  • 1 to 3 lines of prior systemic anticancer therapy
  • Adequate organ function
  • Negative pregnancy test for patients of childbearing potential

Arm C

  • Stage III or IV, recurrent, or metastatic endometrial cancer
  • Life expectancy of ≥3 months
  • ECOG performance status of 0 or 1
  • Able to swallow and retain oral medication
  • Prior treatment with a platinum agent and an approved anti-Programmed Cell Death Ligand 1 (PD[L]1) antibody
  • 1 to 2 lines of prior systemic anticancer therapy for endometrial cancer
  • Must consent to provide an available formalin-fixed paraffin-embedded (FFPE) tumor tissue block or recently cut sections
  • Adequate organ function
  • Negative pregnancy test for patients of childbearing potential

Exclusion Criteria:

Arm A and B

  • Arm A Only: Has progressed while receiving weekly paclitaxel or nab-paclitaxel
  • Prior enrollment in a clinical trial of relacorilant
  • Prior anticancer therapy related toxicities not resolved to grade ≤1
  • Any surgery within 4 weeks prior to enrollment
  • Wide-field radiation to more than 25% of marrow-bearing areas
  • Medical conditions requiring chronic or frequent treatment with corticosteroids
  • Concurrent treatment with mifepristone or other glucocorticoid receptor modulators
  • Peripheral neuropathy from any cause >Grade 1
  • Hypertension: ≥150 mm Hg systolic or ≥100 mm Hg diastolic
  • Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation
  • Bowel obstruction ≤12 weeks prior to study entry
  • Ascites or pleural effusions requiring therapeutic paracentesis
  • Untreated or symptomatic central nervous system metastases
  • History of other malignancy within 3 years prior to enrollment
  • Has received a live vaccine within 30 days prior to the study start date

Arm C

  • Has progressed while receiving weekly paclitaxel or nab-paclitaxel
  • Prior enrollment in a clinical trial of relacorilant
  • Prior anticancer therapy related toxicities not resolved to grade ≤1
  • Any surgery within 4 weeks prior to enrollment
  • Wide-field radiation to more than 25% of marrow-bearing areas
  • Medical conditions requiring chronic or frequent treatment with corticosteroids
  • Concurrent treatment with mifepristone or other glucocorticoid receptor modulators
  • Peripheral neuropathy from any cause >Grade 1
  • Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation
  • Bowel obstruction ≤12 weeks prior to study entry
  • Ascites or pleural effusions requiring therapeutic paracentesis
  • History of other malignancy within 3 years prior to enrollment
  • Has received a live vaccine within 30 days prior to the study start date
  • Patients with central nervous system metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Arm A: Relacorilant in Combination with Nab-paclitaxel and Bevacizumab

In Arm A, patients with platinum-resistant ovarian cancer will receive the combination of relacorilant with nab-paclitaxel and bevacizumab.

Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.

Andere namen:
  • CORT125134

Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.

Bevacizumab is administered as IV infusion on Days 1 and 15.

Experimenteel: Arm B: Relacorilant in Combination with Nab-Paclitaxel and Bevacizumab

In Arm B, patients with platinum-sensitive ovarian cancer who have progressed while receiving treatment with a polymerase inhibitor will receive relacorilant in combination with nab-paclitaxel and bevacizumab.

Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.

Andere namen:
  • CORT125134

Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.

Bevacizumab is administered as IV infusion on Days 1 and 15.

Experimenteel: Arm C: Relacorilant in Combination with Nab-Paclitaxel

In Arm C, patients with previously-treated advanced, recurrent, or metastatic endometrial cancer will receive relacorilant in combination with nab-paclitaxel.

Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.

Andere namen:
  • CORT125134

Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Progression-Free Survival (PFS)
Tijdsspanne: Date of first dose until PD or death, up to 18 months

To evaluate PFS as the time from enrollment until first documented progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as determined by the Investigator, or death due to any cause, whichever occurs first.

Date of first dose until PD or death, up to 18 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Aantal patiënten met een of meer bijwerkingen
Tijdsspanne: Datum van eerste dosis tot 30 dagen na de laatste dosis
Datum van eerste dosis tot 30 dagen na de laatste dosis
Objective Response Rate (ORR)
Tijdsspanne: Date of first dose until PD or death, up to 18 months

To evaluate the proportion of patients with measurable disease at Baseline who attain complete response (CR) or partial response (PR) by RECIST version 1.1.

Date of first dose until PD or death, up to 18 months
Best Overall Response Rate (BOR)
Tijdsspanne: Date of first dose until PD or death, up to 18 months

To evaluate the BOR by RECIST version 1.1 recorded from the date of enrollment until PD or death.

Date of first dose until PD or death, up to 18 months
Duration of Response (DOR)
Tijdsspanne: Time of first objective response until PD or death, up to 18 months

To evaluate DOR as the time from the first CR or PR to first objectively documented PD or death, whichever comes first.

Time of first objective response until PD or death, up to 18 months
Clinical Benefit Rate (CBR)
Tijdsspanne: Week 24

To evaluate CBR as the proportion of patients who attain CR, PR, or stable disease (SD) at Week 24 as per RECIST version 1.1.

Week 24
Overall Survival (OS)
Tijdsspanne: Date of first dose up to 6, 12, and 18 months

To evaluate the probability of OS survival at 6, 12, and 18 months.

Date of first dose up to 6, 12, and 18 months
Area under the plasma concentration-time curve (AUC) of relacorilant
Tijdsspanne: On Cycle 1 Day 8 (each cycle is 28 days)

To estimate exposure of relacorilant. This outcome applies to Arms B and C only.

On Cycle 1 Day 8 (each cycle is 28 days)
Maximum plasma concentration (Cmax) of relacorilant
Tijdsspanne: On Cycle1 Day 8 (each cycle is 28 days)

To estimate exposure of relacorilant. This outcome applies to Arms B and C only.

On Cycle1 Day 8 (each cycle is 28 days)
Trough plasma concentrations (Cmin) of relacorilant
Tijdsspanne: On Cycle 2 Day 8 through the last cycle (up to 12 cycles, each cycle is 28 days)

To estimate exposure of relacorilant. This outcome applies to Arms B and C only.

On Cycle 2 Day 8 through the last cycle (up to 12 cycles, each cycle is 28 days)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Danny Nguyen, MD, Corcept Therapeutics

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

11 april 2025

Primaire voltooiing (Geschat)

1 december 2027

Studie voltooiing (Geschat)

1 augustus 2028

Studieregistratiedata

Eerst ingediend

1 april 2025

Eerst ingediend dat voldeed aan de QC-criteria

1 april 2025

Eerst geplaatst (Werkelijk)

2 april 2025

Updates van studierecords

Laatste update geplaatst (Werkelijk)

16 november 2026

Laatste update ingediend die voldeed aan QC-criteria

10 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren